# GPT-5.2 Review

**Role:** External referee review
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-03-05T17:35:42.072481
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 16439 in / 4691 out
**Response SHA256:** a7c146744eb514e2

---

## Summary

The paper asks a clean and policy-relevant question: did state Right-to-Try (RTT) laws disrupt clinical trial markets? It assembles a large ClinicalTrials.gov dataset and applies modern staggered DiD (Callaway–Sant’Anna, CS) to estimate effects on (i) Phase II/III trial “site counts,” (ii) planned enrollment, and (iii) terminal-condition trial counts. The headline finding is a precisely estimated null for sites and enrollment, with a marginally positive (but multiple-testing-insignificant) estimate for terminal-condition trials.

The topic is plausible for a top field journal and potentially a general-interest outlet if the design and measurement issues are tightened. At present, the causal estimand and the measurement of outcomes—especially what is meant by “trial site counts” and “enrollment by state”—create first-order threats to interpretability and identification. I would view the current draft as **not yet publication-ready** for a top journal, but promising if the authors re-define outcomes to match the disruption hypothesis and show robustness to interference/multi-state trial structure.

---

# 1. Identification and empirical design (critical)

### 1.1 Core identification strategy
- The paper uses staggered DiD exploiting differential RTT adoption timing (2014–2017 within sample; Table “Adoption Timeline”; Sections 3–4).
- Using CS with not-yet-treated controls is appropriate and avoids the worst TWFE pathologies (Section 4.2). This is a strength.

### 1.2 Key concern: outcome definitions may not correspond to the disruption channels
The disruption hypothesis in the introduction/background is primarily about **enrollment and site placement decisions being altered** because terminal patients can access drugs outside trials (Sections 1–2). However, the main “site count” outcome is:

> “number of unique Phase II/III interventional trial IDs listing a facility in the state with a start date in that quarter” (Data section).

This is not a count of sites; it is a **count of trials that have ≥1 facility in the state** in that quarter (and it uses the trial-level start date, not site activation). That makes the estimand closer to “new trials that include at least one facility in state s,” not “site placement intensity” or “trial activity volume in state s.”

Implications:
- A sponsor shifting from 10 sites to 8 sites in a treated state (while keeping at least one site) would not change your main outcome at all.
- Many trials are multi-state; if RTT causes marginal reductions in the number of sites per trial in treated states, the “trial-in-state” indicator could be insensitive.
- Conversely, if RTT leads to *consolidation* (fewer states per trial) without changing total U.S. trial counts, your outcome could move even if total sites do not.

**Concrete fix:** Construct outcomes at the facility level if possible (number of facilities/sites per state-quarter; number of trial–facility observations), or at minimum “number of facilities listed in the state for trials starting in quarter t.” If ClinicalTrials.gov facility records do not include activation dates, you can still count listed facilities per trial at registration/start as a measure of planned site footprint.

### 1.3 SUTVA/interference is plausibly violated and not adequately handled
The paper notes that multi-state trials might reallocate sites from treated to untreated states and argues this would “attenuate toward zero” (Section 4.3). That is not generally correct for the CS estimand with multi-state trials and outcomes that mechanically duplicate trials across states.

Because each multi-state trial is effectively “copied” into multiple state panels:
- A reallocation away from treated states and toward untreated states is precisely the kind of interference that can generate **bias in either direction**, depending on how outcomes are constructed.
- When outcomes are “trial appears in state” indicators, reallocating one facility can flip the indicator only if the last facility is removed; small reallocations might not show up at all.
- With treatment heavily saturated by 2016, the “not-yet-treated” group becomes small and potentially composed of systematically different states, raising sensitivity to spillovers.

**Concrete fix:** Add designs/estimands that reduce interference:
- Run analyses **at the trial level** (e.g., number of states included; total facilities; whether trial includes any treated states at start) with treatment defined by the share of facilities in treated states or the treated status of the lead site. This better matches sponsor planning.
- Alternatively, restrict to **single-state trials** as a robustness exercise (or to trials with a “lead facility state” and focus on that state).
- Provide evidence on multi-state structure trends (mean number of states per trial over time by treated status).

### 1.4 Treatment timing and anticipatory behavior
- You define treatment by adoption quarter and assign outcomes by trial start quarter (Data section; Strategy section). But RTT passage/implementation often occurs mid-quarter; and more importantly, **site selection and trial planning** occur well before the recorded “study start date.” This makes the timing alignment ambiguous in a way that can wash out real effects.
- The “donut” dropping the adoption quarter (Table 6) is helpful but not sufficient because the relevant “decision date” could be several quarters before start.

**Concrete fix:** Use additional timing outcomes:
- Examine trials with **first posted date** or **protocol submission/registration date** if available in the registry, not only start date.
- Include event-time leads longer than 8 quarters and/or explicitly test for **pre-trends/anticipation** in the 1–2 years before adoption, not only 8 quarters binned.

### 1.5 Adoption endogeneity / differential trends
The paper asserts adoption timing was driven by “legislative calendars and lobbying capacity” rather than clinical trial trajectories (Section 2.1; Section 4.3). This is plausible but currently under-substantiated.

Given the summary stats show large level differences (Table 1), the identification depends heavily on **trend comparability**, and adoption could correlate with unobserved time-varying factors (biomedical sector growth, Medicaid expansion environment, cancer center expansions, state research tax credits, etc.).

**Concrete fix:**
- Add covariate-adjusted CS (state-level time-varying controls) or reweighting checks (e.g., incorporate baseline trial intensity and pre-period growth).
- Include cohort-specific pre-trend diagnostics: show pre-trends by early vs late adopters separately.
- Report the **composition of the not-yet-treated control group over time** (which states are serving as controls in which periods).

---

# 2. Inference and statistical validity (critical)

### 2.1 Standard errors and clustering
- You report clustered SEs at the state level for CS and TWFE (Tables 2, Appendix TWFE table). With 51 clusters, asymptotics are more credible than in many policy papers, but top journals increasingly expect **wild cluster bootstrap** or randomization-based inference for key coefficients, especially with staggered timing and serial correlation.

**Concrete fix:** For the main CS estimates, report:
- Wild cluster bootstrap p-values (state-level).
- Alternatively, block-bootstrap over states within CS (the `did` package supports bootstrap-based inference; clarify which inference option is used).

### 2.2 Randomization inference is not aligned with the main estimator
You implement randomization inference (RI) for TWFE (Robustness section; Table 6 notes; Figure RI). But your headline estimates are CS.

**Concrete fix:** Implement RI for the **CS ATT** (or at least for an event-time estimand) using the same permutation scheme. If computationally heavy, do fewer permutations but clearly justify.

### 2.3 Minimum detectable effect (MDE) calculation is too informal
The paper uses “MDE ≈ 2.8 × SE” (Power Analysis section). That heuristic can be misleading with clustered panels, staggered adoption, and CS estimators. Also, the SE you use appears to come from TWFE residual SD logic, not the CS estimator’s actual variance.

**Concrete fix:** Provide a design-consistent power analysis:
- Simulation-based MDE under your actual adoption pattern, clustering, and outcome variance.
- Or use analytical formulas for cluster-randomized DiD, explicitly reporting ICC assumptions and effective number of treated clusters by cohort/time.

### 2.4 Coherence of N / sample across specs
- N is consistently reported as 2,040 state-quarters for main tables, 2,004 for donut, etc. That is coherent.
- However, because the outcomes are constructed from duplicated trial-level variables (multi-state trials counted multiple times), the effective sample size for some outcomes is not obvious. This matters for inference and interpretation.

**Concrete fix:** Add descriptive statistics at the trial level (number of trials; distribution of facilities per trial; distribution of states per trial; how these differ for terminal vs non-terminal conditions).

---

# 3. Robustness and alternative explanations

### 3.1 Robustness to alternative outcome definitions (currently insufficient)
Most robustness checks vary FE structure and drop large states (Table 6), but **do not vary the key measurement choices** that are central to the estimand:
- Counting “trials-with-a-facility” vs “facilities” vs “sites”
- Using start date vs registration date vs first posted date
- Focusing on recruiting/active trials rather than newly starting trials

Given the substantive claim (“did not reduce trial site counts or enrollment”), robustness must show that the null holds for outcomes closer to:
- Site footprint (facility count)
- Enrollment realized (or at least recruitment success proxies)
- Trial continuation/termination

**Concrete fix:** Add outcomes:
- # facilities (trial–facility records) per state-quarter for new trials
- Average facilities per trial in state (conditional on any)
- Trial statuses: probability trial is terminated/withdrawn; time to completion; recruitment status shares
- If possible, actual enrollment (some trials update actual enrollment at completion)

### 3.2 Placebos are sensible but could be stronger
The placebo outcomes (non-terminal, Phase I, observational) are directionally appropriate. However:
- Phase I may still be indirectly affected if sponsors shift overall activity bundles, or if RTT affects perceptions broadly (though you argue it shouldn’t). That’s fine as a placebo but not definitive.
- Non-terminal conditions are constructed via text lists; misclassification could weaken placebo informativeness.

**Concrete fix:** Add a placebo based on a **policy-irrelevant geography** (e.g., outcomes in Canada/non-U.S. facilities if present, or bordering-state discontinuities if you can credibly implement), or a placebo “pseudo-adoption” in pre-2014 periods.

### 3.3 Rambachan–Roth sensitivity: needs reporting detail
You mention HonestDiD bounds but do not report the resulting intervals in the text/tables (Robustness section). For a null paper, this is important: readers need to see how big effects could be under plausible deviations.

**Concrete fix:** Report a table of bounds for key M values for the main outcome, and interpret in % terms.

### 3.4 Alternative explanations
Even if RTT had low take-up, the mechanism you emphasize is “expectations/uncertainty.” If that were the true channel, one might expect:
- Stronger effects early (2014–2015) when uncertainty was highest
- Stronger effects in oncology-heavy states or states with particular liability provisions

**Concrete fix:** Pre-specify heterogeneity by:
- Early adopter period vs later period (uncertainty window)
- Oncology intensity baseline
- Specific statutory features (liability shields, reporting requirements), if variation exists

---

# 4. Contribution and literature positioning

### 4.1 Contribution
The question is novel and interesting: state RTT laws are salient, and a well-powered null can be valuable. The use of registry “universe” data is potentially a contribution, though top journals will view that as **data work in service of identification**, not as a standalone contribution.

### 4.2 Literature gaps / citations to consider
You cover DiD methods (Callaway–Sant’Anna; Goodman-Bacon; de Chaisemartin & D’Haultfoeuille; Rambachan–Roth). You could strengthen positioning by adding:

**ClinicalTrials.gov measurement / registry limitations**
- Zarin et al. work is cited, but consider citations on registration timing and reporting completeness, e.g.:
  - Anderson et al. (2015/2017) on compliance with FDAAA reporting (depending on exact focus)
  - Kaplan & Irvin (2015) on outcome reporting bias (more medical-journal oriented but relevant to registry data reliability)

**Expanded access / compassionate use empirical work**
- There is a small empirical/health policy literature on expanded access and FDA compassionate use approvals that could be cited to support “99% approved quickly” and contextualize take-up and sponsor behavior (beyond Darrow et al.).

**Interference / spillovers in DiD**
- Since multi-state trials create interference, cite and engage with:
  - Sävje, Aronow & Hudgens (2021) or related work on interference
  - Recent applied econometrics discussions of spillovers in DiD (e.g., Goodman-Bacon & Marcus on spillovers; or general DiD-with-interference references)

---

# 5. Results interpretation and claim calibration

### 5.1 Over-claim risk: “trial site counts” and “enrollment”
The abstract and introduction repeatedly state RTT “did not reduce trial site counts or enrollment.” Given your current construction:
- “Site counts” are not site counts; they are trial counts with presence in state.
- “Enrollment” is **planned enrollment duplicated to each state** where a facility exists (Data section footnote). This is not enrollment in that state and is mechanically related to multi-state trial structure.

As written, the conclusion is likely to be viewed as **stronger than the evidence supports**. What you can defend more cleanly is something like:
- “No detectable effect on the number of new Phase II/III trials listing at least one facility in a state” (and similar for terminal-condition trials).
- “No detectable effect on exposure to planned enrollment via trials that include the state,” with clear caveats.

### 5.2 Economic significance claims
You claim an MDE of 7.2% “rules out economically meaningful disruption.” That depends on:
- Whether the estimand matches “disruption” (see above)
- Whether a 7% change in your outcome corresponds to meaningful disruption
- Whether power is uniform across cohorts (late adopters have little post time)

This claim should be weakened unless you redo power/design-consistent inference and align outcomes with disruption.

### 5.3 Terminal-condition positive estimate
You handle this appropriately by not over-interpreting and applying multiple-testing correction. Still, the paper should avoid suggesting it “if anything suggests more activity” unless you can show it is robust to:
- Alternative terminal-condition definitions
- Facility-count outcomes
- Heterogeneity across oncology vs other terminal illnesses

---

# 6. Actionable revision requests (prioritized)

## 1) Must-fix issues before acceptance

1. **Redefine main outcomes to match the causal claim (site placement, enrollment disruption).**  
   - **Why it matters:** The current “trial sites” outcome is not a site count, and the enrollment outcome is not state enrollment. This undermines the main substantive conclusion.  
   - **Concrete fix:** Construct facility-based outcomes (number of facilities per state-quarter for newly starting trials; average facilities per trial; # states per trial). For enrollment, focus on trial-level planned enrollment (not duplicated) and model how RTT affects (i) whether a trial includes treated states, (ii) facility footprint, and (iii) total planned enrollment at the trial level. If site-level enrollment is unavailable, drop/clearly demote “enrollment” as a primary causal endpoint.

2. **Address interference/multi-state trial structure explicitly in the research design.**  
   - **Why it matters:** Spillovers and duplicated outcomes violate SUTVA and can bias DiD. A top journal will not accept “bias toward zero” as a blanket claim.  
   - **Concrete fix:** Add trial-level analysis and/or restrict to single-state trials; show robustness. Report how results change when collapsing to trial-level outcomes.

3. **Align inference with the main estimator and strengthen inference.**  
   - **Why it matters:** The paper’s credibility hinges on correct uncertainty quantification for a null result.  
   - **Concrete fix:** Provide bootstrap/wild-cluster p-values for CS estimates; implement RI for CS ATT (not just TWFE); report HonestDiD bounds in a table for the main outcome.

4. **Clarify treatment timing relative to decision-making and test anticipation more deeply.**  
   - **Why it matters:** RTT could affect planning before “start date”; mis-timed treatment can mechanically generate nulls.  
   - **Concrete fix:** Use registration/first-posted dates if available; extend lead windows; provide “placebo adoption” pre-2014.

## 2) High-value improvements

5. **Report control-group composition over time and cohort balance.**  
   - **Why it matters:** With many states treated by 2016, not-yet-treated controls shrink; estimates may be driven by a small set of never-treated states.  
   - **Concrete fix:** Add a figure/table showing, by quarter, how many states are untreated/not-yet-treated and which they are; report CS weights by cohort/event-time.

6. **Mechanism/heterogeneity tests tied to the narrative (uncertainty, industry behavior).**  
   - **Why it matters:** A null paper is more compelling if it shows predicted “where effects should be strongest” are also null.  
   - **Concrete fix:** Pre-specify and test heterogeneity: early vs late adoption; high oncology-trial states; statutory strength/variation; industry-sponsored vs academic with actual industry-only outcomes (not just industry share discussion).

7. **Power analysis redesign.**  
   - **Why it matters:** “Well-powered null” is central, but current MDE is heuristic.  
   - **Concrete fix:** Simulate power under observed adoption and estimated error structure for the chosen main estimand(s).

## 3) Optional polish (non-essential)

8. **Tighten claim language throughout to match estimands.**  
   - **Why it matters:** Prevents over-claiming and improves referee/editor reception.  
   - **Concrete fix:** Replace “site counts” with “# new trials listing any facility in the state” unless/until true facility counts are used.

9. **Strengthen institutional details with a small statutory-feature dataset.**  
   - **Why it matters:** Helps interpret “symbolic legislation” and allows treatment intensity variation.  
   - **Concrete fix:** Code key RTT provisions and use them for heterogeneity or as an “intensity” treatment.

---

# 7. Overall assessment

### Key strengths
- Important policy question with clear theoretical channels (Background).
- Uses modern staggered DiD (CS) rather than naive TWFE (Empirical Strategy).
- Multiple robustness elements are directionally good for a null result (event studies, placebos, RI, HonestDiD).

### Critical weaknesses
- Main outcomes do not cleanly measure “site counts” or “enrollment disruption,” risking a mismatch between estimand and headline claims (Data section footnotes; Main Results).
- Interference/multi-state trial duplication is a first-order issue not resolved by discussion alone.
- Inference and power claims need to be aligned with the main estimator and the revised outcomes.

### Publishability after revision
Potentially publishable, but only after substantial redesign of outcome measurement and explicit handling of multi-state interference. With those changes, the paper could become a strong and informative “null effect” policy evaluation.

DECISION: MAJOR REVISION